肿瘤浸润淋巴细胞在小HER2阳性乳腺癌中的预后价值
本研究评估肿瘤浸润淋巴细胞(TILs)在pT1a-b期HER2阳性乳腺癌中的预后作用。研究纳入205例淋巴结阴性、pT1a-b期HER2阳性乳腺癌患者,中位随访11年,未发现TILs(连续变量或二分类<50% vs ≥50%)与结局相关。结论认为TILs不能作为该人群的预后生物标志物,仍需其他标志物筛选可降阶梯辅助治疗的患者。
要点
- pT1a-b期HER2阳性乳腺癌中,TILs与预后无显著关联。
- TILs不能作为该人群的预后生物标志物。
- 需其他生物标志物筛选可降阶梯辅助治疗的I期HER2阳性患者。
核心结论
- TILs不能作为pT1a-b期HER2阳性乳腺癌的预后生物标志物。
- 需其他生物标志物筛选可降阶梯辅助治疗的I期HER2阳性乳腺癌患者。
研究设计与样本
- 回顾性研究,从病理档案调取淋巴结阴性、pT1a-b期HER2阳性乳腺癌手术标本的HE切片评估TILs。
- 共纳入205例1997至2009年在欧洲肿瘤研究所接受手术的HER2阳性pT1a-b期乳腺癌患者。
主要发现
- 中位随访11年,TILs作为连续变量或二分类变量(<50% vs ≥50%)均与结局无关联。
- 在未接受辅助治疗的pT1a期患者亚组(36/97例)中,淋巴细胞为主型乳腺癌(LPBC)的无病生存事件率低于非LPBC患者(p = 0.066)。
关键数值与推荐
- TILs评估采用HE切片,二分类界值为<50% vs ≥50%。
- 未接受辅助治疗的pT1a期患者亚组中,LPBC与非LPBC的无病生存事件率比较p = 0.066。
临床怎么用
- 不推荐将TILs用于pT1a-b期HER2阳性乳腺癌的预后判断。
- 对于I期HER2阳性乳腺癌的辅助治疗降阶梯决策,仍需探索其他生物标志物。
局限性
- 回顾性研究,样本来自单一机构。
- 未接受辅助治疗的pT1a期亚组样本量较小(36/97例),LPBC与非LPBC比较的p值为0.066,未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The standard treatment for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)-positive breast cancer (BC) is still controversial. Our aim was to assess the prognostic role of tumour-infiltrating lymphocytes (TILs) in patients with stage pT1a-b HER2-positive BC. PATIENTS AND METHODS: Haematoxylin and eosin slides from node-negative, pT1a-b HER2-positive BC surgical specimens were retrieved from pathology archives to assess TILs and their association with outcome. RESULTS: TILs were evaluated in 205 patients with HER2-positive, pT1a-b tumours, who underwent breast surgery between 1997 and 2009 at the European Institute of Oncology. At a median follow-up of 11 years, we did not observe any association between the presence of TILs, either assessed as a continuous or dichotomous variable (<50 versus ≥ 50%), and outcome. Within the subgroup of patients with pT1a tumours who did not receive any adjuvant therapy (36/97 patients), the rate of disease-free survival events was lower in lymphocyte-predominant BC (LPBC) as compared with non-LPBC patients (p = 0.066). CONCLUSIONS: TILs cannot be used as a prognostic biomarker in pT1a-b HER2-positive BC. Additional biomarkers are needed for selecting patients with stage I HER2-positive BC who candidate to adjuvant therapy de-escalation.
引用
- Criscitiello C, Bagnardi V, Pruneri G, et al. Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. Eur J Cancer. 2017. PMID: 29154173. doi:10.1016/j.ejca.2017.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。